Er Therapeutics Stock Buy Hold or Sell Recommendation
| PNGM Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Er Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Er Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Er Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide. Note, we conduct extensive research on individual companies such as PNGM and provide practical buy, sell, or hold advice based on investors' constraints. Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
PNGM |
Execute Er Therapeutics Buy or Sell Advice
The PNGM recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Er Therapeutics. Macroaxis does not own or have any residual interests in Er Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Er Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Er Therapeutics Trading Alerts and Improvement Suggestions
| Er Therapeutics generated a negative expected return over the last 90 days | |
| Er Therapeutics has some characteristics of a very speculative penny stock | |
| Er Therapeutics currently holds 48.49 K in liabilities. Er Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Er Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (426.95 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Er Therapeutics currently holds about 650 in cash with (161.43 K) of positive cash flow from operations. | |
| Er Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - Quantisnow |
Er Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Er Therapeutics or Metals & Mining sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Er Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PNGM stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Er Therapeutics Volatility Alert
At this time Er Therapeutics exhibits very low volatility. Er Therapeutics appears to be a penny stock. Although Er Therapeutics may be, in fact, a solid short-term or long term investment, many penny stocks are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Er Therapeutics or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on PNGM instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Er Therapeutics Fundamentals Vs Peers
Comparing Er Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Er Therapeutics' direct or indirect competition across all of the common fundamentals between Er Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Er Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Er Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Er Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Er Therapeutics to competition |
| Fundamentals | Er Therapeutics | Peer Average |
| Return On Asset | -0.95 | -0.14 |
| Current Valuation | 122.36 K | 16.62 B |
| Shares Outstanding | 58.26 M | 571.82 M |
| Price To Earning | (0.06) X | 28.72 X |
| Price To Book | 143,650 X | 9.51 X |
| Net Income | (426.95 K) | 570.98 M |
| Cash And Equivalents | 650 | 2.7 B |
| Total Debt | 48.49 K | 5.32 B |
| Current Ratio | 0.01 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (161.43 K) | 971.22 M |
| Beta | 10.4 | -0.15 |
| Market Capitalization | 332.11 K | 19.03 B |
| Total Asset | 423.6 K | 29.47 B |
| Working Capital | (638 K) | 1.48 B |
| Current Asset | 7 K | 9.34 B |
| Current Liabilities | 645 K | 7.9 B |
| Net Asset | 423.6 K |
Er Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PNGM . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Er Therapeutics Buy or Sell Advice
When is the right time to buy or sell Er Therapeutics? Buying financial instruments such as PNGM Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Er Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Iron Thematic Idea Now
Iron
Companies involved in production of steel and iron. The Iron theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Er Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.